Vietnam Ophthalmic Drugs Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Vietnam Ophthalmic Drugs Market Overview

• The Vietnam Ophthalmic Drugs Market is valued at USD 470 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of eye diseases such as glaucoma, cataracts, diabetic retinopathy, and age-related macular degeneration, rising healthcare expenditure, and advancements in ophthalmic drug formulations and delivery systems. The market has seen a surge in demand for innovative therapies, particularly in the areas of anti-VEGF agents and anti-glaucoma medications, which are crucial for managing chronic retinal and optic nerve disorders in an aging population.
• Key cities such as Ho Chi Minh City and Hanoi dominate the market due to their advanced healthcare infrastructure, higher concentration of tertiary hospitals and specialized eye care facilities, and greater availability of ophthalmologists. These urban centers are also home to a higher population density and higher disposable incomes, leading to increased patient footfall, higher diagnosis rates, and stronger demand for branded and innovative ophthalmic drugs. The presence and expansion of leading international and local pharmaceutical companies, along with well-developed distribution networks in these regions, further enhance market growth and accessibility to advanced treatments.
• In 2023, the Vietnamese government strengthened the regulatory framework governing the quality, safety, and efficacy of ophthalmic drugs through instruments such as the Law on Pharmacy 2016 and its implementing Decree No. 54/2017/ND-CP, as amended by Decree No. 155/2018/ND-CP, issued by the National Assembly and the Government of Vietnam. These regulations mandate that all pharmaceutical products, including ophthalmic drugs, undergo registration with the Ministry of Health, with documented clinical data, quality dossiers, and compliance with Good Manufacturing Practice and pharmacovigilance requirements before approval and circulation. This framework is part of a broader strategy to enhance public health standards, align with international quality benchmarks, and promote the use of safe and effective advanced medical therapies.

Vietnam Ophthalmic Drugs Market Segmentation

By Drug Class:The ophthalmic drugs market is segmented into various drug classes, including anti-allergy, anti-VEGF agents, anti-inflammatory, anti-glaucoma, gene & cell therapy, and others. Among these, anti-VEGF agents are currently one of the leading segments in value due to their effectiveness in treating retinal diseases and age-related macular degeneration and the increasing burden of diabetic retinopathy in Vietnam. At the same time, recent industry assessments indicate that anti-glaucoma drugs constitute the dominant class by volume and patient use, reflecting the high prevalence of glaucoma and the need for long-term intraocular pressure control. Anti-inflammatory drugs also hold a significant share, as they are essential for managing post-operative care, ocular surface disease, and a range of inflammatory eye conditions following cataract and refractive procedures.

By Drug Disease / Indication:This segmentation includes categories such as dry eye, allergies, glaucoma, retinal disorders, uveitis, and others. The dry eye segment is currently one of the most prominent, driven by lifestyle changes, aging, urban air pollution, and increased screen time, all contributing to higher prevalence and greater use of lubricants and prescription dry eye therapies. Allergies also represent a significant portion of the market, as allergic conjunctivitis and related conditions are common in urban and industrialized areas, supporting demand for anti-allergy eye drops. Rising diagnosis and treatment of retinal disorders, including diabetic retinopathy and neovascular age-related macular degeneration, along with increased use of intravitreal injections, are contributing to rapid expansion of the retinal disorders segment.

Vietnam Ophthalmic Drugs Market Competitive Landscape

The Vietnam Ophthalmic Drugs Market is characterized by a dynamic mix of regional and international players. Leading participants such as Novartis Pharma Vietnam Company Limited, Santen Pharmaceutical Co., Ltd., Alcon Vietnam Company Limited, Bayer Vietnam Ltd., Johnson & Johnson Vision Care, Merck Sharp & Dohme (MSD) Vietnam Co., Ltd., Pfizer (Vietnam) Limited, GlaxoSmithKline (GSK) Vietnam Co., Ltd., AbbVie Vietnam Co., Ltd., Eyevance Pharmaceuticals, Bausch + Lomb Vietnam, Hoya Corporation, Otsuka Pharmaceutical Co., Ltd., Laboratoires Théa, Aerie Pharmaceuticals, Inc. contribute to innovation, geographic expansion, and service delivery in this space.

Vietnam Ophthalmic Drugs Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Eye Diseases:The prevalence of eye diseases in Vietnam is rising, with an estimated 3.5 million people affected by cataracts alone in future. Additionally, the World Health Organization reports that around 1.5 million individuals suffer from diabetic retinopathy. This growing burden of eye diseases is driving demand for ophthalmic drugs, as healthcare providers seek effective treatments to manage these conditions and improve patient outcomes.
• Rising Geriatric Population:Vietnam's geriatric population is projected to reach 14.5 million in future, representing approximately 15% of the total population. This demographic shift is significant, as older adults are more susceptible to eye diseases such as glaucoma and age-related macular degeneration. Consequently, the increasing number of elderly individuals is expected to boost the demand for ophthalmic drugs, creating a robust market for pharmaceutical companies.
• Advancements in Ophthalmic Drug Formulations:The Vietnamese pharmaceutical sector is witnessing rapid advancements in ophthalmic drug formulations, with over 20 new products launched in future alone. Innovations such as sustained-release formulations and targeted therapies are enhancing treatment efficacy and patient compliance. These advancements are expected to drive market growth, as healthcare providers increasingly adopt these innovative solutions to address complex eye conditions effectively.

Market Challenges

• High Cost of Innovative Treatments:The introduction of innovative ophthalmic treatments often comes with high costs, with some therapies exceeding 10 million VND per treatment cycle. This financial burden can limit access for many patients, particularly in lower-income segments. As a result, healthcare providers may face challenges in prescribing these advanced therapies, hindering overall market growth and patient access to necessary treatments.
• Limited Access in Rural Areas:Approximately 70% of Vietnam's population resides in rural areas, where access to specialized eye care services is severely limited. In future, only 30% of rural residents have access to ophthalmologists, creating significant disparities in treatment availability. This limited access poses a challenge for the ophthalmic drugs market, as many patients may not receive timely diagnoses or treatments, impacting overall market potential.

Vietnam Ophthalmic Drugs Market Future Outlook

The Vietnam ophthalmic drugs market is poised for significant growth, driven by demographic shifts and technological advancements. As the geriatric population expands and the prevalence of eye diseases increases, demand for innovative treatments will rise. Furthermore, the integration of digital health solutions and telemedicine is expected to enhance patient access to care. Pharmaceutical companies that invest in research and development will likely capitalize on these trends, positioning themselves favorably in this evolving landscape.

Market Opportunities

• Expansion of Telemedicine Services:The Vietnamese government aims to increase telemedicine services, with a target of reaching 50% of healthcare facilities in future. This expansion will facilitate remote consultations and improve access to ophthalmic care, particularly in underserved areas, creating new opportunities for ophthalmic drug providers to reach a broader patient base.
• Increasing Investment in Healthcare Infrastructure:Vietnam's healthcare expenditure is projected to grow to 7.5% of GDP in future, driven by government initiatives to enhance healthcare infrastructure. This investment will likely improve access to ophthalmic services and increase the demand for ophthalmic drugs, presenting significant opportunities for pharmaceutical companies to expand their market presence.